New PCR test spots drug-resistant tuberculosis fast and affordably

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis are a growing global health challenge because they make infections harder to treat and control. Rapid, accurate, and affordable molecular diagnostics are needed to identify drug resistance early so patients receive the right therapy and public health teams can respond. In response to this need, a team led by Pratap N. Mukhopadhyaya designed and analytically validated a new testing platform: a multiplex real-time PCR assay that combines contact-quenching fluorescence detection with allele-specific primers and 3′ blocked wild-type allele blockers. Rather than relying on a single probe or machine, the system is modular and built to be scalable, offering a potential cost-effective alternative to commercial diagnostics. The developers report this is the first application of contact-quenching-based allele-specific PCR specifically aimed at detecting MDR TB mutations, and they emphasize the platform’s compatibility with routine lab workflows and multiple fluorescence channels to support robust testing in diverse laboratory settings.

The test targets five clinically important resistance-associated mutations in the rpoB, katG, and inhA genes: rpoB codons 516, 526, 531; katG codon 315; and inhA (–)15 promoter. To create reliable positive controls, the team engineered synthetic double-stranded linear DNA constructs carrying individual point mutations using Splicing by Overlap Extension (SOEing), and they confirmed those constructs by Sanger sequencing. These synthetic controls were mixed into a background of wild-type genomic DNA from clinical isolates to test performance. The multiplex qPCR platform uses contact-quenching fluorescence detection together with allele-specific primers and 3′ blocked wild-type allele blockers to preferentially amplify mutant sequences. Analytically, the assay achieved detection limits of 25 to 50 copies per reaction, detected mutant alleles even when a 70-fold excess of wild-type DNA was present, and showed consistent amplification efficiency (92 to 104%). The assay also demonstrated minimal cross-reactivity, reliable performance under PCR-inhibitory conditions, inclusion of internal amplification controls, and compatibility with multiple fluorescence channels.

Taken together, these analytical results suggest a practical tool for early drug resistance surveillance and patient management. High specificity and sensitivity, low detection limits, and the ability to identify mutants in a large excess of wild-type DNA mean the assay could pick up resistance earlier than some traditional methods. Its modular design and compatibility with standard fluorescence channels make it adaptable to different laboratory setups, and the use of synthetic mutation standards keeps quality control straightforward. Because the platform is presented as scalable and cost-effective, it has potential for deployment in decentralized settings where rapid decisions about therapy and infection control are most needed. By offering an alternative to more expensive commercial diagnostics, this contact-quenching-based allele-specific PCR system could broaden access to molecular testing for MDR and XDR Mycobacterium tuberculosis and strengthen local surveillance efforts.